NIH National Cancer Institute

Supports cancer-focused research from prevention to treatment, including translational projects, clinical networks, and innovation pathways.

National Cancer Institute (NCI) is NIH's cancer-focused institute and the largest public funder of cancer research. It sits within NIH and HHS, but it has its own statutory authority under the National Cancer Act and a yearly budget of about $7.35 billion.

NCI funds Research Project Grants, cancer centers, SPOREs, clinical trial networks, training, and small-business routes, including NIH-wide SBIR and STTR participation plus NCI-direct contract work. Award sizes in the portfolio range from $50,000 for the small grants program to $300,000 for IMAT, $500,000 for bioengineering research grants, and up to $25 million for Cancer Grand Challenges. Those routes cover both investigator-initiated work and large collaborative efforts.

NCI is a strong fit for cancer tools, diagnostics, therapeutics, and translational platforms that can survive two-level review. Applicants do best when they can place their work inside a clear cancer use case and a mechanism that matches the stage, because the institute separates small grants, platform work, and major collaborative programs rather than treating them as one lane.